title: Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis.
abstract: BACKGROUND
  Short-term mortality rates among patients with HIV receiving antiretroviral therapy (ART) in sub-Saharan Africa are higher than those recorded in high-income countries, but systematic long-term comparisons have not been made because of the scarcity of available data. We analysed the effect of the implementation of Botswana's national ART programme, known as Masa, from 2002 to 2010.
  
  
  METHODS
  The Masa programme started on Jan 21, 2002. Patients who were eligible for ART according to national guidelines had their data collected prospectively through a clinical information system developed by the Botswana Ministry of Health. A dataset of all available electronic records for adults (≥18 years) who had enrolled by April 30, 2010, was extracted and sent to the study team. All data were anonymised before analysis. The primary outcome was mortality. To assess the effect of loss to follow-up, we did a series of sensitivity analyses assuming varying proportions of the population lost to follow-up to be dead.
  
  
  RESULTS
  We analysed the records of 126,263 patients, of whom 102,713 had documented initiation of ART. Median follow-up time was 35 months (IQR 14-56), with a median of eight follow-up visits (4-14). 15,270 patients were deemed lost to follow-up by the end of the study. 63% (78,866) of the study population were women; median age at baseline was 34 years for women (IQR 29-41) and 38 years for men (33-45). 10,230 (8%) deaths were documented during the 9 years of the study. Mortality was highest during the first 3 months after treatment initiation at 12·8 deaths per 100 person-years (95% CI 12·4-13·2), but decreased to 1·16 deaths per 100 person-years (1·12-1·2) in the second year of treatment, and to 0·15 deaths per 100 person-years (0·09-0·25) over the next 7 years of follow-up. In each calendar year after the start of the Masa programme in 2002, average CD4 cell counts at enrolment increased (from 101 cells/μL [IQR 44-156] in 2002, to 191 cells/μL [115-239] in 2010). In each year, the proportion of the total enrolled population who died in that year decreased, from 63% (88 of 140) in 2002, to 0·8% (13 of 1599) in 2010. A sensitivity analysis assuming that 60% of the population lost to follow-up had died gave 3000 additional deaths, increasing overall mortality from 8% to 11-13%.
  
  
  CONCLUSIONS
  The Botswana national HIV/AIDS treatment programme reduced mortality among adults with HIV to levels much the same as in other low-income or middle-income countries.
  
  
  BACKGROUND
  The African Comprehensive HIV/AIDS Partnerships.
authors.affiliation: Harvard School of Public Health, Boston, MA, USA. Electronic address: mfarahan@hsph.harvard.edu.
authors.forename: Mansour
authors.initials: M
authors.lastname: Farahani
authors.affiliation: Harvard School of Public Health, Boston, MA, USA.
authors.forename: Anusha
authors.initials: A
authors.lastname: Vable
authors.affiliation: Ministry of Health, Gaborone, Botswana.
authors.forename: Refeletswe
authors.initials: R
authors.lastname: Lebelonyane
authors.affiliation: Ministry of Health, Gaborone, Botswana.
authors.forename: Khumo
authors.initials: K
authors.lastname: Seipone
authors.affiliation: Ministry of Health, Gaborone, Botswana.
authors.forename: Marina
authors.initials: M
authors.lastname: Anderson
authors.affiliation: Ministry of Health, Gaborone, Botswana.
authors.forename: Ava
authors.initials: A
authors.lastname: Avalos
authors.affiliation: Ministry of Health, Gaborone, Botswana.
authors.forename: Tim
authors.initials: T
authors.lastname: Chadborn
authors.affiliation: Harvard School of Public Health, Boston, MA, USA.
authors.forename: Hailu
authors.initials: H
authors.lastname: Tilahun
authors.affiliation: Harvard School of Public Health, Boston, MA, USA.
authors.forename: Danae
authors.initials: D
authors.lastname: Roumis
authors.affiliation: African Comprehensive HIV/AIDS Partnerships, Gaborone, Botswana.
authors.forename: Themba
authors.initials: T
authors.lastname: Moeti
authors.affiliation: African Comprehensive HIV/AIDS Partnerships, Gaborone, Botswana.
authors.forename: Godfrey
authors.initials: G
authors.lastname: Musuka
authors.affiliation: African Comprehensive HIV/AIDS Partnerships, Gaborone, Botswana.
authors.forename: Lesego
authors.initials: L
authors.lastname: Busang
authors.affiliation: Botswana-Harvard Partnership, Gaborone, Botswana.
authors.forename: Tendani
authors.initials: T
authors.lastname: Gaolathe
authors.affiliation: Ministry of Health, Gaborone, Botswana.
authors.forename: Kolaatamo C S
authors.initials: KC
authors.lastname: Malefho
authors.affiliation: Harvard School of Public Health, Boston, MA, USA; Botswana-Harvard Partnership, Gaborone, Botswana.
authors.forename: Richard
authors.initials: R
authors.lastname: Marlink
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001902:Botswana / Q000453:epidemiology; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D015497:HIV-1; D006801:Humans; D008137:Longitudinal Studies; D059012:Lost to Follow-Up; D008297:Male; D008875:Middle Aged; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents